Is Cyteir Therapeutics, Inc. (CYT) a Buy, Sell, or Hold?
NASDAQ : CYT
Cyteir Therapeutics, Inc.
$3.02 USD
-$0.07 (-2.27%)
- Volume
- 1.01M
- Average Volume
- 171.44K
- Market Capitalization
- $108.71M
- P/E Ratio
- -2.42
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $3.19
- Year Low
- $1.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $28.07
Company Overview
NASDAQ
Markus F. Renschler
Biotechnology
Healthcare
CYT
46
US
USD
Liquidity Metrics
0.01
28.07
28.07
27.68
0.00
Sales & Valuation
-$
0.00
0.73
-2.54
-1.21
Profitability
-$1.25
-$43.95M
0.00%
0.00%
-26.35%
-28.68%
P/E Metrics
-2.42
-0.05
-0.05
Analyst Price Target & Rating
$2.00
$2.00
$2.00
0/5
5 Analysts
51.00%
Financial Health Scores
9.37
1/9
$124.67M
$131.01M
$5.98M
-$37.64M
Key Metrics (TTM)
-$37.52M
0.00
0.81
28.07
-26.35%
-32.37%
-41.26%
-39.41%
-299 days
Company Executives
| Name | Title |
|---|---|
| Markus F. Renschler | President, Chief Executive Officer & Director |
| Kevin Mills | Co-Founder |
| Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board |
| David G. Gaiero | Chief Financial Officer & Treasurer |
Poll Results
No votes yet today — be the first to share your view!
About Cyteir Therapeutics, Inc. (NASDAQ:CYT) Stock
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts. ...
Frequently Asked Questions
-
What is the current Cyteir Therapeutics, Inc. (CYT) stock price?
-
Cyteir Therapeutics, Inc.(NASDAQ:CYT) stock price is $3.02 in the last trading session. During the trading session, CYT stock reached the peak price of $3.19 while $1.65 was the lowest point it dropped to. The percentage change in CYT stock occurred in the recent session was --2.27% while the dollar amount for the price change in CYT stock was -$0.07.
-
CYT's industry and sector of operation?
-
The NASDAQ listed CYT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYT?
-
Markus F. Renschler | President, Chief Executive Officer & Director
Kevin Mills | Co-Founder
Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board
David G. Gaiero | Chief Financial Officer & Treasurer
| -
How many employees does CYT have?
-
Number of CYT employees currently stands at 46. CYT operates from 128 Spring Street, Lexington, MA 02421, US.
-
Link for CYT official website?
-
Official Website of CYT is: https://cyteir.com
-
How do I contact CYT?
-
CYT could be contacted at phone #857 285 4140 and can also be accessed through its website. CYT operates from 128 Spring Street, Lexington, MA 02421, US.
-
How many shares of CYT are traded daily?
-
The average number of CYT shares traded daily for last 3 months was 171.44K.
-
What is the market cap of CYT currently?
-
The market value of CYT currently stands at $108.71M with its latest stock price at $3.02